Heart drug may shield breast cancer patients from chemo damage
NCT ID NCT07233499
First seen Nov 18, 2025 · Last updated Apr 29, 2026 · Updated 19 times
Summary
This study tests whether a heart medication called nebivolol can prevent heart damage caused by trastuzumab, a common breast cancer drug. About 56 adults with HER2-positive breast cancer will take nebivolol or a placebo during their cancer treatment. The goal is to see if nebivolol helps keep the heart pumping normally and improves quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Institute- Cairo University- Egypt
RECRUITINGCairo, Egypt
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.